Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Trial Details

NCT ID

NCT03678025

Phase

PHASE3

Sponsor

SWOG Cancer Research Network

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Abiraterone
Bicalutamide
Degarelix
Docetaxel
Flutamide
Goserelin Acetate

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Phoenix, Arizona, United States|33.44838,-112.07404
Phoenix, Arizona, United States|33.44838,-112.07404
Scottsdale, Arizona, United States|33.50921,-111.89903
Tucson, Arizona, United States|32.22174,-110.92648

Key Eligibility Criteria

STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the p…
STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed…
STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have evidence of metastatic disease on technetium bone scan and computed tomography (C…
STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients with known brain metastases are not eligible. Brain imaging studies are not required for el…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →